Table 2.
Baseline demographic and clinical characteristics of the CHPS cohort
| Characteristic | Participants (N = 56) |
|---|---|
| Median age at enrollment, y (ROV) | 1.63 (1‐2.5) |
| Family history of hemophilia, n (%) | |
| Yes | 18 (32) |
| No | 38 (68) |
| Genotype, n (%) | |
| Null mutationa | 43 (77) |
| Non‐null mutationb | 6 (11) |
| Unknown | 7 (12) |
| CVAD placed prior to study entry, n (%) | 56 (100) |
| Yes | 15 (26.8) |
| No | 41 (73.2) |
| No inhibitor at baseline, n (%) | 56 (100) |
| Enrollment center, n (%) | |
| Hamilton | 10 (17.9) |
| Montreal | 10 (17.9) |
| Winnipeg | 9 (16.1) |
| Toronto | 8 (14.3) |
| Calgary | 7 (12.5) |
| Quebec City | 5 (8.9) |
| Ottawa | 2 (3.6) |
| Saskatoon | 2 (3.6) |
| Halifax | 1 (1.8) |
| Thunder Bay | 1 (1.8) |
| Vancouver | 1 (1.8) |
a
Defined by intron 22 and intron 1 inversions, nonsense mutations, large deletions, small deletions/insertions outside poly‐A runs, or splice‐site mutations involving conserved nucleotides.33
b
Defined by missense mutations, small deletions/insertions within poly‐A runs, or splice‐site mutations involving nonconserved nucleotides33.